Developing optimal pediatric COVID-19 vaccines for children younger than 12 years during an evolving pandemic

Flor M  Muñoz; Charu Sabharwal; Alejandra  Gurtman; Emmanuel B  Walter; Grant C  Paulsen; Eric AF Simões; Caitlin  Hansen; Luke  Cunliffe; Stephen Lockhart; Hua  Ma; Xia  Xu; Kenneth  Koury; Kena A  Swanson; Nicholas  Kitchin; William C Gruber; Annaliesa S  Anderson

doi:10.18609/vac/2023.037

Developing optimal pediatric COVID-19 vaccines for children younger than 12 years during an evolving pandemic

Vaccine Insights 2023; 2(7), 249–254

10.18609/vac/2023.037

Published: 27 July 2023

Viewpoint

Flor M Muñoz, Charu Sabharwal, Alejandra Gurtman, Emmanuel B Walter, Grant C Paulsen, Eric AF Simões , Caitlin Hansen, Luke Cunliffe, Stephen Lockhart, Hua Ma, Xia Xu, Kenneth Koury, Kena A Swanson, Nicholas Kitchin, William C Gruber, Annaliesa S Anderson

“With children potentially susceptible to future variants, and calls from the FDA and WHO for an XBB monovalent variant vaccine for the 2023/2024 season, vaccine development will continue to ensure our youngest are protected.”

CLINICAL DEVELOPMENT: SEIZING POST-PANDEMIC OPPORTUNITIES TO ENHANCE THE CLINICAL TRIAL ECOSYSTEM

Developing optimal pediatric COVID-19 vaccines for children younger than 12 years during an evolving pandemic

Vaccine Insights 2023; 2(7), 249–254

10.18609/vac/2023.037

“With children potentially susceptible to future variants, and calls from the FDA and WHO for an XBB monovalent variant vaccine for the 2023/2024 season, vaccine development will continue to ensure our youngest are protected.”